• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pediatr Hematol Oncol . Coronavirus Disease 2019 in Pediatric Oncology Patients: A Matched-Cohort Analysis of the SCCM Discovery Viral Infection

tetano

Editor, Senior Moderator
J Pediatr Hematol Oncol


. 2022 Dec 12.
doi: 10.1097/MPH.0000000000002588. Online ahead of print.
Coronavirus Disease 2019 in Pediatric Oncology Patients: A Matched-Cohort Analysis of the SCCM Discovery Viral Infection and Respiratory Illness Universal Study COVID-19 Registry


Niveditha Balakumar[SUP] 1 [/SUP], Samanta Catueno[SUP] 2 [/SUP], Meghana Nadiger[SUP] 3 [/SUP], Prithvi Raj Sendi Keshavamurthy[SUP] 4 [/SUP], Balagangadhar R Totapally[SUP] 4 [/SUP], Farha Sherani[SUP] 5 [/SUP], Nkechi Mba[SUP] 5 [/SUP], Katja M Gist[SUP] 6 [/SUP], Sandeep Tripathi[SUP] 3 7 [/SUP], Ognjen Gajic[SUP] 8 [/SUP], Neha Deo[SUP] 8 [/SUP], Vishakha Kumar[SUP] 9 [/SUP], Allan Walkey[SUP] 10 [/SUP], Rahul Kashyap[SUP] 8 [/SUP], Utpal S Bhalala[SUP] 2 11 [/SUP]



Affiliations

Abstract

Background: There is a paucity of multicenter data describing the impact of coronavirus disease 2019 (COVID-19) on hospitalized pediatric oncology patients. Using a large, multicenter, Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness University Study (VIRUS) database, we aimed at assessing outcomes of COVID-19 infection in this population.
Method: This is a matched-cohort study involving children below 18 years of age hospitalized with COVID-19 between March 2020 and January 2021. Using the VIRUS; COVID-19 Registry database, children with oncologic diseases were compared with propensity score matched (age groups, sex, race, and ethnicity) cohort of children without oncologic diseases for the prevalence of Multisystem Inflammatory Syndrome in Children (MIS-C), intensive care unit (ICU) admission, interventions, hospital, and ICU length of stay.
Results: The number of children in the case and control groups was 45 and 180, respectively. ICU admission rate was similar in both groups ([47.7 vs 51.7%], P=0.63). The proportion of children requiring noninvasive and invasive mechanical ventilation, and its duration were similar between groups, same as hospital mortality. Interestingly, MIS-C was significantly lower in the oncology group compared with the control (2.4 vs 24.6%; P=0.0002).
Conclusions: In this study using a multicenter VIRUS database, ICU admission rate, interventions, and outcomes of COVID-19 were similar in children with the oncologic disease compared with control patients. The incidence of MIS-C is lower in oncologic patients.
 
Back
Top Bottom